Key Takeaways Solventum to acquire Acera Surgical for $725M upfront and$125M tied to milestones.Acera Surgical's synthetic matrix tech fits SOLV's wound care portfolio, adding care solutions.Solventum expects slight EPS dilution in 2026, with earnings accretion from 2027.Solventum (SOLV) announced the acquisition of Acera Surgical, which specializes in advanced synthetic treatment options for regenerative wound care, to expand its MedSurg business into the fast-growing synthetic tissue matrices market with ...